Skip to main content

Chimerix Stock Forecast, Price & News

-0.02 (-0.24 %)
(As of 05/13/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume411,638 shs
Average Volume996,925 shs
Market Capitalization$702.62 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Chimerix logo

About Chimerix

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CMRX
Year FoundedN/A

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share


Net Income$-112,580,000.00
Net Margins-321.31%




Market Cap$702.62 million
Next Earnings Date8/9/2021 (Estimated)


Overall MarketRank

1.71 out of 5 stars

Medical Sector

254th out of 2,038 stocks

Pharmaceutical Preparations Industry

108th out of 769 stocks

Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

Is Chimerix a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix
or view top-rated stocks.

What stocks does MarketBeat like better than Chimerix?

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chimerix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Chimerix

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) released its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.73. Chimerix had a negative trailing twelve-month return on equity of 36.57% and a negative net margin of 321.31%.
View Chimerix's earnings history

How has Chimerix's stock price been impacted by Coronavirus?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 466.0% and is now trading at $8.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CMRX?

5 Wall Street analysts have issued 12 month target prices for Chimerix's stock. Their forecasts range from $14.00 to $21.00. On average, they anticipate Chimerix's share price to reach $18.80 in the next twelve months. This suggests a possible upside of 130.7% from the stock's current price.
View analysts' price targets for Chimerix
or view top-rated stocks among Wall Street analysts.

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 55, Pay $869.4k)
  • Mr. Michael T. Andriole M.B.A., Chief Bus. Officer, Sec. & CFO (Age 48, Pay $539.79k)
  • Dr. Michael A. Alrutz, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51, Pay $619.5k)
  • Mr. David Jakeman, Exec. Director of Fin. & Accounting and Principal Accounting Officer (Age 44)
  • Dr. Roy W. Ware, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier, Chief Science Officer
  • Ms. Michelle LaSpaluto, VP of Strategic Planning & Investor Relations
  • Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer
  • Dr. Joshua E. Allen, Chief Technology Officer of Imipridones

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.29%), Renaissance Technologies LLC (3.29%), Geode Capital Management LLC (1.45%), New Leaf Venture Partners L.L.C. (1.42%), Northern Trust Corp (0.71%) and Acadian Asset Management LLC (0.38%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix

Which major investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, New Leaf Venture Partners L.L.C., JPMorgan Chase & Co., Renaissance Technologies LLC, GSA Capital Partners LLP, Alliancebernstein L.P., Vanguard Capital Wealth Advisors, and Bank Julius Baer & Co. Ltd Zurich. Company insiders that have sold Chimerix company stock in the last year include David Jakeman, and Martha J Demski.
View insider buying and selling activity for Chimerix
or view top insider-selling stocks.

Which major investors are buying Chimerix stock?

CMRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, UBS Group AG, Russell Investments Group Ltd., Citigroup Inc., Rafferty Asset Management LLC, Northern Trust Corp, and Barclays PLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
or or view top insider-buying stocks.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $8.15.

How much money does Chimerix make?

Chimerix has a market capitalization of $702.62 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Chimerix have?

Chimerix employs 54 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is

Where are Chimerix's headquarters?

Chimerix is headquartered at 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.